CA2750835C - Carboxamide compounds and methods for using the same - Google Patents

Carboxamide compounds and methods for using the same Download PDF

Info

Publication number
CA2750835C
CA2750835C CA2750835A CA2750835A CA2750835C CA 2750835 C CA2750835 C CA 2750835C CA 2750835 A CA2750835 A CA 2750835A CA 2750835 A CA2750835 A CA 2750835A CA 2750835 C CA2750835 C CA 2750835C
Authority
CA
Canada
Prior art keywords
alkyl
haloalkyl
compound according
independently selected
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2750835A
Other languages
English (en)
French (fr)
Other versions
CA2750835A1 (en
Inventor
Ihab S. Darwish
Hui Hong
Rajinder Singh
Xiang Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigel Pharmaceuticals Inc
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of CA2750835A1 publication Critical patent/CA2750835A1/en
Application granted granted Critical
Publication of CA2750835C publication Critical patent/CA2750835C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N61/00—Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2750835A 2009-01-28 2010-01-28 Carboxamide compounds and methods for using the same Active CA2750835C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14798209P 2009-01-28 2009-01-28
US61/147,982 2009-01-28
PCT/US2010/022411 WO2010088392A1 (en) 2009-01-28 2010-01-28 Carboxamide compounds and methods for using the same

Publications (2)

Publication Number Publication Date
CA2750835A1 CA2750835A1 (en) 2010-08-05
CA2750835C true CA2750835C (en) 2018-09-04

Family

ID=42061132

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2750835A Active CA2750835C (en) 2009-01-28 2010-01-28 Carboxamide compounds and methods for using the same

Country Status (17)

Country Link
US (2) US8362235B2 (https=)
EP (1) EP2391616B1 (https=)
JP (1) JP5658688B2 (https=)
KR (1) KR101693061B1 (https=)
CN (1) CN102365275B (https=)
AU (1) AU2010208247B2 (https=)
BR (1) BRPI1007287B8 (https=)
CA (1) CA2750835C (https=)
EA (1) EA022083B1 (https=)
ES (1) ES2581678T3 (https=)
IL (1) IL214203A (https=)
MX (1) MX2011007639A (https=)
NZ (1) NZ594556A (https=)
SG (1) SG172974A1 (https=)
UA (1) UA106600C2 (https=)
WO (1) WO2010088392A1 (https=)
ZA (1) ZA201105215B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0911681B8 (pt) * 2008-04-23 2021-05-25 Rigel Pharmaceuticals Inc composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula in vitro
WO2011123681A1 (en) 2010-03-31 2011-10-06 Rigel Pharmaceuticals, Inc. Methods for using carboxamide, sulfonamide and amine compounds
PE20130774A1 (es) * 2010-07-29 2013-06-26 Rigel Pharmaceuticals Inc Compuestos heterociclicos activadores de ampk y metodos para emplearlos
US9005909B2 (en) 2011-01-06 2015-04-14 Rigel Pharmaceuticals, Inc. Whole blood assay for measuring AMPK activation
US9409884B2 (en) 2012-02-01 2016-08-09 Rigel Pharmaceuticals, Inc. 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2970177A1 (en) 2013-03-15 2016-01-20 Pfizer Inc. Indole compounds that activate ampk
US20150087673A1 (en) * 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
US20160214967A1 (en) 2013-09-30 2016-07-28 The University Of Tokyo Activator of adiponectin receptor
JP7346425B2 (ja) 2018-01-11 2023-09-19 セントラス セラピューティクス 疾患を治療するためのジヒドロセラミドデサチュラーゼ阻害剤
US12194023B2 (en) 2018-11-29 2025-01-14 The Research Foundation For The State University Of New York Compositions and methods for modular control of bioorthogonal ligation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
KR100579792B1 (ko) * 1998-05-13 2006-05-12 동화약품공업주식회사 신규 2,5-피리딘디카복실산 유도체
US7109199B2 (en) * 2000-09-22 2006-09-19 Smithkline Beecham Corporation Pyrazolopyridines and pyrazolopyridazines as antidiabetics
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
EP1965862A2 (en) * 2005-12-21 2008-09-10 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
ATE507205T1 (de) 2006-12-11 2011-05-15 Genetics Co Inc Aromatische 1,4-di-carboxylamide und deren verwendung
US8012955B2 (en) 2006-12-28 2011-09-06 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
NZ585298A (en) 2007-11-16 2012-08-31 Rigel Pharmaceuticals Inc Carboxamide, sulfonamide and amine compounds for metabolic disorders
EP2231666B1 (en) * 2007-12-12 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
BRPI0911681B8 (pt) * 2008-04-23 2021-05-25 Rigel Pharmaceuticals Inc composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula in vitro
WO2011123681A1 (en) 2010-03-31 2011-10-06 Rigel Pharmaceuticals, Inc. Methods for using carboxamide, sulfonamide and amine compounds

Also Published As

Publication number Publication date
WO2010088392A1 (en) 2010-08-05
ZA201105215B (en) 2012-09-26
KR101693061B1 (ko) 2017-01-04
IL214203A0 (en) 2011-08-31
JP5658688B2 (ja) 2015-01-28
MX2011007639A (es) 2011-09-15
NZ594556A (en) 2013-11-29
AU2010208247A1 (en) 2011-08-11
UA106600C2 (uk) 2014-09-25
SG172974A1 (en) 2011-08-29
EP2391616B1 (en) 2016-03-30
ES2581678T3 (es) 2016-09-06
US8846600B2 (en) 2014-09-30
EA201170979A1 (ru) 2012-02-28
AU2010208247B2 (en) 2015-06-18
BRPI1007287B1 (pt) 2021-03-09
US8362235B2 (en) 2013-01-29
BRPI1007287B8 (pt) 2021-05-25
EP2391616A1 (en) 2011-12-07
JP2012516349A (ja) 2012-07-19
CA2750835A1 (en) 2010-08-05
EA022083B1 (ru) 2015-10-30
CN102365275B (zh) 2014-09-24
HK1164860A1 (zh) 2012-09-28
CN102365275A (zh) 2012-02-29
IL214203A (en) 2015-01-29
US20100190802A1 (en) 2010-07-29
KR20110119755A (ko) 2011-11-02
US20130131078A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
CA2750835C (en) Carboxamide compounds and methods for using the same
EP2598483B1 (en) Ampk-activating heterocyclic compounds and methods for using the same
CA2674237C (en) N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
EP2276761B1 (en) Carboxamide compounds for the treatment of metabolic disorders
CA2705947C (en) Carboxamide, sulfonamide and amine compounds for metabolic disorders
CA2707047A1 (en) Carboxamide, sulfonamide and amine compounds for metabolic disorders
EP3500558B1 (en) Benzimidazole direct ampk activators
HK1164860B (en) Carboxamide compounds and methods for using the same
HK1152939B (en) Carboxamide compounds for the treatment of metabolic disorders
HK1148525B (en) Carboxamide, sulfonamide and amine compounds for metabolic disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150123

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20240731